Compensating Participants in Clinical Research: Current Thinking

Sponsors, researchers and Institutional Review Boards (IRBs) are often wary about payments in research participation, citing concerns about coercion and undue influence, whether real or perceived, and have avoided payments that are “too high.” New research on how people make decisions about research participation, and new approaches to this question, bring a new perspective; are payments to participants actually too low? This paper explores this question, and whether we should, in fact, worry much less about restricting compensation for research participants.Enter content here

Previous Flipbook
IRBs can make the most of central IRB partnerships
IRBs can make the most of central IRB partnerships

The IRB at Inova Health System of Falls Church, VA, began working with a central IRB 15 years ago. Since th...

Next Post
Limited IRB Review: Are You Prepared for January 21st?
Limited IRB Review: Are You Prepared for January 21st?

On January 21, 2019, most federally funded research will need to follow the 2018 Requirements of the Common...

New Blog: "Ask the IRB Experts"

Visit Blog